Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Naomi M. Simon, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00113295
First received: June 7, 2005
Last updated: March 20, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to examine the safety and efficacy of quetiapine for generalized anxiety disorder patients who remain symptomatic despite treatment with paroxetine CR.


Condition Intervention Phase
Anxiety Disorder
Drug: Continued Paroxetine CR
Drug: Quetiapine
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Hamilton Anxiety Scale (HAM-A) Score at Study Endpoint. [ Time Frame: Baseline and Week 18 ] [ Designated as safety issue: No ]

    Symptoms of generalized anxiety disorder as measured by the Hamilton Anxiety Scale (HAM-A) at week 18/study endpoint. Each item is scored on a scale from 0 (not present) to 4 (severe) with a total score range of 0-56. Changes in HAM-A scores are calculated as the difference between the baseline HAM-A scores and scores at week 18/study endpoint.

    The 14-item Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1959) was developed to assess anxiety in a clinical population. It is considered a measure of general anxiety across anxiety disorders, in addition to being a gold standard measure for GAD.



Secondary Outcome Measures:
  • Remission (HAM-A ≤ 7) [ Time Frame: Week 18 (Study Endpoint) ] [ Designated as safety issue: No ]
    Remission was measured as a secondary outcome using a score of less than or equal to 7 on the Hamilton Anxiety Scale (HAM-A).

  • Response, Clinical Global Impression of Improvement (CGI-I) [ Time Frame: Week 18 (Phase 2 Endpoint) ] [ Designated as safety issue: No ]
    Response was measured as a secondary outcome using the Clinical Global Impression of Improvement (CGI-I). Response was defined as a score of 1 ["very much improved"] or 2 ["much improved"] at study endpoint.

  • Depressive Symptoms, Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: Week 10 (Phase 1 Endpoint) and Week 18 (Phase 2 Endpoint) ] [ Designated as safety issue: No ]
    Depressive symptoms were measured at a secondary outcome using the Montgomery-Asberg Depression Rating Scale (MADRS). Each item is scored on a scale of 1-6; The total score range is 0-60, with higher scores indicated higher levels of depression severity.

  • The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). [ Time Frame: Week 10 (Phase 1 Endpoint) and Week 18 (Phase 2 Endpoint) ] [ Designated as safety issue: No ]
    The 16-item Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) is used to assess quality of life changes with treatment. Total scores range from 14-70, with higher levels of satisfaction yielding higher scores.


Enrollment: 50
Study Start Date: February 2004
Study Completion Date: November 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Paroxetine CR and Placebo
Eleven individuals were randomized to plaecbo augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly titrated up to a maximum of 62.5 mg/day by week 10. Individuals who did not achieve remission and were randomized into the placebo group received placebo augmentation of continued paroxetine CR at the week 10 dose level.
Drug: Continued Paroxetine CR Drug: Placebo
Experimental: Quetiapine and continued paroxetine CR
Eleven individuals were randomized to quetiapine augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly tirated up to a maximum of 62.5 mg/day by week 10. Individuals who did not receive remission and were randomized to receive quetiapine started at 25 mg at bedtime for the first week, then flexibly dosed based on response and tolerability to a maximum of 200 mg BID by week 16.
Drug: Continued Paroxetine CR Drug: Quetiapine

Detailed Description:

Generalized anxiety disorder (GAD) is a relatively common condition affecting 5% of the population, with a typically chronic course and associated with significant psychosocial impairment and decreased quality of life (Schweizer, 1995). Although a number of therapeutic agents demonstrate some efficacy in the treatment of generalized anxiety disorder, only a minority of anxious patients experience remission with initial treatment.

The purpose of this study is to examine the efficacy of one strategy, the addition of quetiapine, for the treatment of patients with GAD who remain refractory despite an adequate treatment trial with a selective serotonin reuptake inhibitor (SSRI). This is an investigator-initiated augmentation study of an already approved drug for a different indication. Quetiapine is a novel antipsychotic agent with potent effects at the serotonergic, as well as dopaminergic receptor, and a more favorable side effect profile than standard neuroleptics, including a low potential to cause extrapyramidal symptoms.

This is a two phase, 18-week research study in which participants who remain symptomatic at the end of one phase (10 weeks) enter into the next phase. In phase I, all participants receive paroxetine CR (Paxil CR) for 10 weeks. Participants who continue to have anxiety symptoms will enter the 8-week Phase II, in which they continue taking Paxil CR and they will also be randomly assigned (by chance, like a flip of a coin) to receive quetiapine (Seroquel) or placebo (contains no active medication).

  Eligibility

Ages Eligible for Study:   18 Years to 72 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female outpatients, age 18-72.
  • Primary diagnosis of generalized anxiety disorder.
  • Patients on concurrent benzodiazepines will be entered into the trial if they remain symptomatic despite stable doses for at least one month

Exclusion Criteria:

  • Pregnant or lactating women or other women of child bearing potential not using acceptable means of birth control
  • Patients with a primary diagnosis of major depression, dysthymia, panic disorder or social phobia.
  • Patients with current or history of bipolar disorder, schizophrenia or other psychotic conditions
  • Patients with post-traumatic stress disorder or obsessive-compulsive disorder current in the past 6 months.
  • Patients with a history of alcohol or substance abuse or dependence within the last six months.
  • Patients with significant unstable medical illness.
  • Ongoing psychotherapy directed toward the treatment of generalized anxiety disorder.
  • History of hypersensitivity to paroxetine CR, paroxetine or quetiapine.
  • History of cataracts.
  • Concurrent use of psychotropic medications including buspirone and antidepressants. Patients must have discontinued buspirone or antidepressant therapy at least two weeks prior to study entry, and fluoxetine at least four weeks prior, but no patient will be taken off effective medication.
  • Concomitant use of herbs and dietary supplements with known psychotropic properties, including St John's Wort, Kava, Valerian, Gingko, Ginseng, ephedra and weight loss supplements. Other than such agents with known psychotropic properties, no over the counter medications are exclusionary.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00113295

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Naomi M Simon, MD Massachusetts General Hospital
Principal Investigator: Kathryn Connors, MD Duke University
  More Information

Additional Information:
No publications provided

Responsible Party: Naomi M. Simon, Director, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00113295     History of Changes
Other Study ID Numbers: 2003-P001805
Study First Received: June 7, 2005
Results First Received: May 16, 2013
Last Updated: March 20, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
generalized anxiety disorder
pharmacotherapy
treatment refractory
double-blind

Additional relevant MeSH terms:
Anxiety Disorders
Disease
Mental Disorders
Pathologic Processes
Paroxetine
Quetiapine
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on October 20, 2014